Skip to main content

Table 4 Analysis of efficacy of weekly irinotecan and capecitabine as first- or second line treatment

From: Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

Variable First-line treatment (n = 30) Second-line treatment (n = 22)
  Number (%) 95% CI Number (%) 95% CI
Overall survival
Deaths 16 (53.3)   12 (54.5)  
Median OS (months) 16.3 10.47–22.13 10.7 5.80–15.60
Progression-free survival
Progression events 25 (83.3)   20 (90.9)  
Median PFS (months) 8.5 6.22–10.78 5.0 1.74–8.26
Response 27   21  
ORR 10 (37.0)   3 (14.3)  
PR 10 (37.0)   3 (14.3)  
SD 11 (40.7)   13 (61.9)  
PD 6 (22.2)   5 (23.8)  
Treatment cycles
Total 378   266  
Median number of cycles (range) 12 (1–50) 12 (1–33)
Median treatment period (months) 3.7   3.7  
  1. CR: complete response; ORR: overall response rate; OS: overall survival; PD: progressive disease; PFS: progression-free survival; PR: partial response; SD: stable disease.
\